Search research articles
Contact Us
Filters
Showing results (1-10 of 62) with videos related to
Page
of 7
Sort By:
JACC. Heart Failure
|
October 17, 2017
The Risks and Benefits of Moderate Alcohol Consumption: There Remains Much to Learn
Eric S Leifer
Biometrics
|
April 5, 2019
Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall
Eric S Leifer, Nancy L Geller
Contemporary Clinical Trials
|
June 6, 2006
Comparison of two or more measurement techniques to a standard
Michael A Proschan, Eric S Leifer
JACC. Heart Failure
|
October 11, 2020
Patient-Centered Measures of Treatment Benefit
Eric S Leifer, Robert J Mentz
JACC. Cardiovascular Imaging
|
May 6, 2017
The Authors Reply
Andrew E Arai, Eric S Leifer, Vandana Sachdev
Statistics in Medicine
|
May 1, 2018
Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?
James F Troendle, Eric S Leifer, Lauren Kunz
Clinical Trials (London, England)
|
August 19, 2021
Joint testing of overall and simple effects for the two-by-two factorial trial design
Eric S Leifer, James F Troendle, Alexis Kolecki, et al.
Statistics in Medicine
|
October 7, 2025
Sensitivity Analyses for Missing in Repeatedly Measured Outcome Data
James F Troendle, Aparajita Sur, Eric S Leifer, et al.
Circulation. Heart Failure
|
May 15, 2025
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State
Eric S Leifer, James F Troendle, Mitchell A Psotka, et al.
Pediatric Cardiology
|
April 14, 2011
Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events
Jeffrey P Moak, Eric S Leifer, Dorothy Tripodi, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 62) with videos related to
Sort By:
Page
of 7
JACC. Heart Failure
|
October 17, 2017
The Risks and Benefits of Moderate Alcohol Consumption: There Remains Much to Learn
Eric S Leifer
Biometrics
|
April 5, 2019
Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall
Eric S Leifer, Nancy L Geller
Contemporary Clinical Trials
|
June 6, 2006
Comparison of two or more measurement techniques to a standard
Michael A Proschan, Eric S Leifer
JACC. Heart Failure
|
October 11, 2020
Patient-Centered Measures of Treatment Benefit
Eric S Leifer, Robert J Mentz
JACC. Cardiovascular Imaging
|
May 6, 2017
The Authors Reply
Andrew E Arai, Eric S Leifer, Vandana Sachdev
Statistics in Medicine
|
May 1, 2018
Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?
James F Troendle, Eric S Leifer, Lauren Kunz
Clinical Trials (London, England)
|
August 19, 2021
Joint testing of overall and simple effects for the two-by-two factorial trial design
Eric S Leifer, James F Troendle, Alexis Kolecki, et al.
Statistics in Medicine
|
October 7, 2025
Sensitivity Analyses for Missing in Repeatedly Measured Outcome Data
James F Troendle, Aparajita Sur, Eric S Leifer, et al.
Circulation. Heart Failure
|
May 15, 2025
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State
Eric S Leifer, James F Troendle, Mitchell A Psotka, et al.
Pediatric Cardiology
|
April 14, 2011
Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events
Jeffrey P Moak, Eric S Leifer, Dorothy Tripodi, et al.
Page
of 7